BMS-986012 in Relapsed/Refractory SCLC
The purpose of this study is to determine the safety, tolerability, pharmacokinetics, immunogenicity, antitumor activity and pharmacodynamics of BMS-986012 alone and in combination with nivolumab in patients with relapsed/refractory SCLC.
Checked against the public recordLast updated Mar 5, 2024 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Sponsor
- Bristol-Myers Squibb
- Interventions being studied
- Biological: BMS-986012 (anti-fucosyl-GM1); Biological: Nivolumab
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Histological or cytological confirmed small cell lung cancer (SCLC) * Performance Status 0-1 * Adequate organ function * Measurable disease Exclusion Criteria: * Known or suspected brain metastasis * Small cell cancer not lung in origin * Significant or acute medical illness * Uncontrolled or significant cardiac disease * Infection * ≥ Grade 2 peripheral neuropathy * Concomitant malignancies * HIV related disease or known or suspected HIV+ * Hepatitis B or C infection * ECG abnormalities as defined by the protocol * Allergies or hypersensitivities to monoclonal antibodies, BMS-986012 or related compounds, including fucosyl-GM1 vaccine and Nivolumab Other protocol defined inclusion/exclusion criteria could apply
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Local Institution - 0004New York, New York
- Local Institution - 0001Durham, North Carolina
- Local Institution - 0021Winston-Salem, North Carolina
- Local Institution - 0020St Leonards, New South Wales
- Local Institution - 0011Brisbane, Queensland
- Local Institution - 0002Clayton, Victoria
- Local Institution - 0015Ghent
- Local Institution - 0012Liège
- Local Institution - 0003Edmonton, Alberta
- Local Institution - 0017Halifax, Nova Scotia
- Local Institution - 0019Hamilton, Ontario
- Local Institution - 0010London, Ontario
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Mar 5, 2024. Always confirm current availability with the study team.